From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfunction leads to increased apoptosis and blast prolifer...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostics (Basel) 2021-10, Vol.11 (11), p.1982
Main Authors: Comont, Thibault, Treiner, Emmanuel, Vergez, François
Format: Article
Language:English
Subjects:
Aging
Apoptosis
Cloning
Cytokines
Disease
DNA methylation
immune
Immune system
Infections
Inflammation
Kinases
Life Sciences
Ligands
Medical prognosis
Mutation
Myelodysplastic syndromes
Pathophysiology
Proteins
Review
Stem cells
T-cell
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfunction leads to increased apoptosis and blast proliferation. Addressing immune dysregulations in MDS is a recent concept that has allowed the identification of new therapeutic targets. Several approaches targeting the different actors of the immune system have therefore been developed. However, the results are very heterogeneous, indicating the need to improve our understanding of the disease and interactions between chronic inflammation, adaptive dysfunction, and somatic mutations. This review highlights current knowledge of the role of immune dysregulation in MDS pathophysiology and the field of new drugs.
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics11111982